AARTIDRUGS Aarti Drugs Q4 FY26 results (Jan–Mar 2026) and concall
Aarti Drugs reported a strong sequential recovery in Q4 FY26, driven by robust formulation growth and ramp-up of its methylamine plant. Despite facing macroeconomic headwinds and elevated input costs, the company achieved significant QoQ EBITDA growth. Management outlined plans for continued capacity expansion and margin improvement, while addressing challenges in salicylic acid production and potential impacts of high API prices on domestic antibiotic demand.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 6.4%, net profit down 12.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 598 | 557 | 677 | 591 | 653 +9% | 602 +8% | 720 +6% |
| EBITDA | 67 | 62 | 93 | 74 | 84 +25% | 55 −11% | 96 +3% |
| Net profit | 35 | 37 | 63 | 54 | 45 +29% | 41 +11% | 55 −13% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
